Reza Maulana, Viskasari Pintoko Kalanjati

= http://dx.doi.org/10.20473/mbiom.v25i2.2012.27-32
Abstract views = 145 times | downloads = 166 times


Parkinson’s disease is one of neurodegenerative diseases which is the second most common afterAlzheimer’s disease in the world. It is a chronic disease with selective loss of dopaminergic neurons withinthe substantia nigra (SN) pars compacta (pc) of the midbrain. The disease represents a complex interactionbetween the inherent vulnerability of the nigrostriatal dopaminergic system, a possible geneticpredisposition, and exposures to environmental toxins including inflammatory triggers. Until now, the exactcause of Parkinson’s disease remains uncertain, but recent studies suggest neuroinflammation andmicroglia activation play important roles in Parkinson’s disease pathogenesis. Evidence now suggest thatchronic neuroinflammation and systemic inflammation are consistently associated with the patophysiologyof Parkinson’s disease. Activated microglia and increased level of pro-inflammatory cytokine such as TumorNecrosis Factor (TNF)-α, interleukin (IL)-2, IL-6, RANTES, Reactive Oxygen Species (ROS) and NitricOxide (NO) have been reported from Parkinson’s disease patients and in animal models of Parkinson’sdisease. The blood brain barrier permeability dysfunction is also a contributing factor to the pathology ofthis disease. In this review, we discuss about neuronal cell pathology in Parkinson’s disease, its possiblerelationship with neuroinflammation and systemic inflammation, blood brain barrier disfunction and proinflammatory cytokine released during the disease’s progressivity. Lastly, we also review theepidemiological data suggest about the inflammation and the increased risk of Parkinson’s disease. Moreresearch are needed to undercover the role of inflammation in Parkinson’s disease. With a betterunderstanding about the relationship between inflammation and Parkinson’s disease cross-talk, the brightfuture with the possibility of specific immunomodulatory drugs play a role to limit a progressivity ofParkinson’s disease is no longer just a dream.


Parkinson’s disease; inflammation; microglia;pro-inflammatory cytokine; Penyakit parkinson; peradangan; mikroglia; sitokin pro-inflamasi

Full Text:



Broussolle, E. et al., 1999. Relation of putamenand caudate nucleus F-Dopa uptake to motorand cognitive performances in Parkinson’s disease. Journal of the NeurologicalScience, 166, hal.141-151.

Carr, J., 2001. Tremor in Parkinson’s disease.Parkinsonism and Related Disorder, 8,hal.223-234.

Cersosimo, M. G. & Benarroch, E.E., 2011.Autonomic involvement in Parkinson'sdisease: Pathology, pathophysiology,clinical features and possible peripheralbiomarkers. Journal of the NeurologicalSciences, 313, hal.57-63.

Chen, H. et al., 2008. Peripheral inflammatorybiomarkers and risk of Parkinson's disease.Am J Epidemiol.,167, hal.150-157.

Collins, L.M. Toulouse, A. Connor, T.J. & Nolan,Y.M., 2012. Contributions of central andsystemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology, 62, hal.2154-2168.

Colpan, M.E. & Slavin, K., 2010. Subthalamic andred nucleus volumes in patients withParkinson’s disease: do they change withdisease progression? Parkinsonism andRelated Disorders, 16, hal.398-403.

Couch, Y. et al., 2011. The acute inflammatoryresponse to intranigral α-synuclein differssignificantly from intranigral lipopolysaccharides and is exacerbated by peripheralinflammation. Journal of Neuroinflammation, 8(166), hal.1-14.

Durrenberger, P.F. et al., 2012. Inflammatorypathways in Parkinson's disease; A BNEmicroarray study. Parkinson's Disease.2012.

Farkas, S. et al., 2012. The decrease of dopamineD2/D3 receptor densities in the putamen andnucleus caudatus goes parallel withmaintained levels of CB1 cannabinoidreceptors in Parkinson’s disease: apreliminary autoradiographic study with theselective dopamine D2/D3 antagonist[3H]raclopride and the novel CB1 inverseagonist [125I] SD7015. Brain ResearchBulletin, 87, hal.504– 510.

Ginsberg, L. 2008. Lecture notes: neurologi. Edisike-8. Jakarta: Penerbit Erlangga, hal.100-111.

Greenberg, D.A. Aminoff, M.J. & Simon, R.P.,2002. Clinical neurology. Edisi ke-5. USA:Lange medical books/ McGraw-Hill,hal.234-246.

Halliday, G.M. et al., 1996. Midbrain neuropathology in idiopathic Parkinson's diseaseand diffuse Lewy body disease. Neuroscience, 3, hal.52-60.

Helmich, R.C. et al., 2012. Cerebral causes andconsequences of Parkinsonian restingtremor: a tale of two circuits? Brain, hal.1-21.

Hernandez, R.C. et al., 2012. Peripheral inflammation increases the deleterious effect of CNSinflammation on the nigrostriatal dopaminergic system. Neurotoxicology, 33,hal.347-360.

Hirsch, E.C., 1999. Mechanism and consequencesof nerve cell death in Parkinson's disease.In: Przuntek, h. dan Muller, T. (eds.)Diagnosis and treatment of Parkinson'sdisease-state of the art. Wien: SpringerVerlag, hal.127-137.

Huang, Y. & Halliday, G.M., 2012. Aspects ofinnate immunity and Parkinson's disease.Frontiers in Pharmacology, 3.hal.1-10.

Huot, P. Fox, S.H. & Brotchie, J.M., 2011. Theserotonergic system in Parkinson’s disease.Progress in Neurobiology, 95, hal.163-212.

Jang H. et al., 2009. Highly pathogenic H5N1influenza virus can enter the central nervoussystem and induce neuroinflammation andneurodegeneration. Proc. Natl. Acad. Sci.US., 106, hal.14063-14068.

Kostic, V.S. & Filippi, M., 2011. Neuroanatomicalcorrelates of depression and apathy inParkinson's disease: magnetic resonanceimaging studies. Journal of the NeurologicalSciences, 310, hal.61-63.

Kyrkanides, S. et al., 2011. Osteoarthritisaccelerates and exacerbates Alzheimer'sdisease pathology in mice. Journal ofneuroinflammation, 8(112).

Machado, A. et al., 2011. Peripheral inflammationincreases the damage in animal models ofnigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson'sdisease incidence. Parkinson's Disease.

Mosley, R.L. Hutter-Sauders, J.A. Stone, D.K. &Gendelman, H.E., 2012. Inflammation andadaptive immunity in Parkinson's disease.Cold Spring Harb Perspect Med., 2:a009381.

Ogata, A. et al., 1997. A rat model of Parkinson'sdisese induced by Japanese encephalitisvirus. J. Neurovirol., 3, hal.141-147.

Paus, S. et al., 2011. Tremor in Parkinson’s diseaseis not associated with the DRD3 Ser9Glypolymorphism. Parkinsonism Relat. Disord.,16, hal.381-383.

Poser C.M. Huntley C.J & Poland J.D., 1969.Para-encephalitic Parkinsonism. Report ofan acute case due to coxsackie virus type B2 and re-examination of the etiologicconcepts of postencephalitic Parkinsonism.Acta Neurol. Scand., 45, hal.199-215.

Pranzatelli M.R. et al., 1994. Clinical spectrum ofsecondary Parkinsonism in childhood: areversible disorder. Pediatr. Neurol., 10,hal.131-140.

Qin, L. et al., 2007. Systemic LPS causes chronicneuroinflammation and progressiveneurodegeneration. Glia, 55(5), hal.453-462.

Rail, D. Scholtz, C. dan Swash, M., 1981. Postencephalitic Parkinsonism: current experience. J. Neurol. Neurosurg. Psychiatrr.,44, hal.670-676.

Reale, M. et al., 2009. Peripheral cytokine profilein Parkinson's disease. Brain Behav.Immun., 23, hal 55-63.

Robinson, R.L. et al., 2003. Transient Parkinsonism in West Nile virus encephalitis. Am. J.Med., 115, hal.252-253.

Rohn, T.T. & Catlin, L.W., 2011. Immunolocalization of influenza A virus andmarkers of inflammation in the humanParkinson's disease brain. Plos one,6(5):e20495.

Salehi, Z. & Mashayekhi, F., 2009. Brain-derivedneurotrophic factor concentrations in thecerebrospinal fluid of patients withParkinson’s disease. Journal of ClinicalNeuroscience, 16, hal.90-93.

Takahashi M. et al., 1995. The substantia nigra is amajor target for neurovirulent influenza Avirus. J. Exp. Med., 181, hal.2161-2169.

Tansey, M.G. & Goldberg, M.S., 2010. Neuroinflammation in Parkinson's disease: its rolein neuronal death and implications fortheurapeutic intervention. Neurobiol Dis.,37(3), hal.510-518.

Tansey, M.G. Mccoy, M.K. & Frank-Cannon,T.C., 2007. Neuroinflammatory mechanismin Parkinson's disease: potential environmental triggers, pathways, and targets forearly therapeutic intervention. Exp. Neurol.,208, hal.1-25.

Thornton, E. & Vink, R., 2012. Treatment with asubstance P receptor antagonist is neuroprotective in the intrastriatal 6-Hydroxydopamine model of early Parkinson'sdisease. Plos One, 7(4):e34138.

Tse, W. et al., 2004. Movement disorders andAIDS: a review. Parkinsonism Relat.Disord., 10, hal.323-334.


  • There are currently no refbacks.

Copyright (c) 2019 Majalah Biomorfologi

Creative Commons License
Majalah Biomorfologi (p-ISSN:0215-8833; e-ISSN:2716-0920) is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

View Majalah Biomorfologi Statistics


 Indexed By